Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ARS Pharmaceuticals ( (SPRY) ) has provided an update.
On June 25, 2025, ARS Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders. During this meeting, stockholders elected four Class II directors to serve until the 2028 Annual Meeting. Additionally, the stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (SPRY) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
Spark’s Take on SPRY Stock
According to Spark, TipRanks’ AI Analyst, SPRY is a Neutral.
ARS Pharmaceuticals’ strong revenue growth and positive technical indicators are significant strengths, but challenges in profitability and valuation weigh down the overall score. The promising market entry of Neffy and strategic collaborations are positive, yet high operating expenses and net loss present risks.
To see Spark’s full report on SPRY stock, click here.
More about ARS Pharmaceuticals
Average Trading Volume: 1,483,624
Technical Sentiment Signal: Buy
Current Market Cap: $1.7B
For a thorough assessment of SPRY stock, go to TipRanks’ Stock Analysis page.